Annovis Bio Shares Surge on Positive Parkinson’s Study Data

Annovis Bio (ANVS) has provided an update.

Annovis Bio, Inc. has revealed exciting new data from its Phase III Parkinson’s study, capturing the attention of the stock market and financial observers. The announcement was made through a press release and the company has scheduled a detailed webcast discussion for the evening of July 2, 2024. Interested parties can find the registration details for this event on the company’s website under the Investors section.

For detailed information about ANVS stock, go to TipRanks’ Stock Analysis page.